Existing literature indicates that communication between the central nervous system and the
peripheral nervous system is disrupted by substance use disorders (SUDs), including …

FGF21 is an endocrine hormone that controls key metabolic processes and induces the
synthesis of glucose transporters, resulting in increased glucose absorption levels in fat …

Alcohol use disorder (AUD) is the most prevalent substance use disorder worldwide.
Acamprosate and naltrexone are anti-craving drugs used in AUD pharmacotherapy …

Objective Fibroblast growth factor 21 (FGF21) analogs have been tested as potential
therapeutics for substance use disorders. Prior research suggests that FGF21 administration …

Acamprosate is an anti-craving drug used in alcohol use disorder (AUD) pharmacotherapy.
However, only a subset of patients achieves optimal treatment outcomes. The identification …

Background Alcohol use disorder (AUD) affects 5% of the global population. Despite its high
prevalence, the pathophysiology of AUD remains enigmatic, hindering the development of …

Acamprosate is a Food and Drug Administration (FDA) approved medication for the
treatment of alcohol use disorder (AUD). However, only a subset of patients achieves …

Introduction Patients with alcohol use disorder (AUD) often experience repeated withdrawal.
Impulsivity is the most relevant factor influencing successful withdrawal. Brain-derived …

Growing evidence indicates that the crosstalk between the central nervous system and the
periphery plays an important role in the pathophysiology of neuropsychiatric conditions …

Fibroblast growth factor 21 (FGF21) is a liver-derived hormone known to suppress alcohol
consumption in mice and non-human primates. However, the role of FGF21 in modulating …